Abstract
In this issue of Cancer Discovery, Adams and colleagues present the discovery of a potent PROTAC, MDM2 degrader, which activates wild-type p53 leading to cancer cell death. Importantly, in a number of in vitro and in vivo experiments, the authors show that the depletion of MDM2 by PROTAC kills p53-mutant or p53-null cancer cells. See related article by Adams et al., p. 1210 (5).
©2023 American Association for Cancer Research.
Publication types
-
Editorial
-
Research Support, Non-U.S. Gov't
-
Comment
MeSH terms
-
Antineoplastic Agents* / pharmacology
-
Antineoplastic Agents* / therapeutic use
-
Humans
-
Proto-Oncogene Proteins c-mdm2 / metabolism
-
Triple Negative Breast Neoplasms*
-
Tumor Suppressor Protein p53 / genetics
-
Tumor Suppressor Protein p53 / metabolism
Substances
-
Tumor Suppressor Protein p53
-
Proto-Oncogene Proteins c-mdm2
-
Antineoplastic Agents
-
MDM2 protein, human